Spectrofluorometric determination of montelukast in dosage forms and spiked human plasma.
The native fluorescence of montelukast has been studied under different experimental conditions. The highest fluorescence intensity was obtained in methanol at 390 nm using 340 nm for excitation. Surfactants and sensitizers had either a negative or a slightly positive effect on its fluorescence intensity. The fluorescence intensity-concentration plot was rectilinear over the range 0.125 to 5 microg/ml with a lower detection limit of 0.02 microg/ml (3.4 x 10(-8) M). Interference likely to be introduced from co-formulated drugs (such as loratadine) or co-administered drugs (such as verapamil, carbazepam, propranolol) or other common drugs, was studied. The method was successfully applied to the determination of the drug in tablets (pediatric tablets, chewable tablets and adult tablets). The mean % recoveries were in agreement with those provided by the manufacturer. The method was further applied to the in vitro determination of montelukast in spiked human plasma, the mean % recovery (n = 5) was 100.08 +/- 1.40.
Alsarra
I
I
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Khalil
N Y
NY
Sultan
M
M
Al-Ashban
R
R
Belal
F
F
D000085:Acetates / Q000032:analysis* / Q000097:blood; D018927:Anti-Asthmatic Agents / Q000032:analysis* / Q000097:blood; D002851:Chromatography, High Pressure Liquid; D003521:Cyclopropanes; D004304:Dosage Forms; D007202:Indicators and Reagents; D016014:Linear Models; D011804:Quinolines / Q000032:analysis* / Q000097:blood; D015203:Reproducibility of Results; D013050:Spectrometry, Fluorescence; D013056:Spectrophotometry, Ultraviolet; D013440:Sulfides; D013607:Tablets
D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D004304:Dosage Forms; D007202:Indicators and Reagents; D011804:Quinolines; D013440:Sulfides; D013607:Tablets; C093875:montelukast